Jaguar Health, Inc. Reports 2021 First Quarter Financial Results First quarter 2021 Mytesi gross sales and net sales were approximately $4.6 million and approximately $1.2 million, increases of 250% and 43%, respectively

Jaguar Health, Inc. Reports 2021 First Quarter

First quarter 2021 Mytesi gross sales and net

sales were approximately $4.6 million and approximately $1.2 million, increases of 250% and 43%, respectively

Company to host investor webcast Monday, May

17th at 8:30 a.m. Eastern regarding first quarter 2021 financials & business updates

SAN FRANCISCO, CA / May 17, 2021 / Jaguar Health, Inc.

(NASDAQ: JAGX) ("Jaguar" or the "Company") today reported consolidated first quarter 2021 financial results.

2021 First Quarter Company Financial Results:

Note Regarding Use of Non-GAAP Measures

The Company supplements its condensed consolidated financial statements

presented on a GAAP basis by providing gross sales, non-GAAP EBITDA, and non-GAAP recurring EBITDA, which are considered non-GAAP under

applicable SEC rules. Jaguar believes that the disclosure items of these non-GAAP measures provide investors with additional information

that reflets the basis upon which Company management assesses and operates the business. These non-GAAP financial measures are not in

accordance with GAAP and should not be viewed in isolation or as substitutes for GAAP net sales and GAAP net loss and are not substitutes

for, or superior to, measures of financial performance in conformity with GAAP.

Gross sales percentages issued by the Company are based on gross sales

figures that represent Mytesi orders placed by wholesalers with Jaguar's third-party logistics warehouse, less allowances for rebates,

chargebacks, and discounts, which generate the cash flows for Napo. Gross sales are used internally by management as an indicator of and

to monitor operating performance, including sales performance of Mytesi, salesperson performance, and product growth or declines. The

Company believes that the presentation of gross sales provides a closer to real-time useful measure of our operating performance. Gross

sales are not a measure that is recognized under accounting principles generally accepted in the United States of America ("GAAP")

and should not be considered as an alternative to net sales, which is determined in accordance with GAAP, and should not be used alone

as an indicator of operating performance in place of net sales. Additionally, gross sales may not be comparable to similarly titled measures

used by other companies, as gross sales have been defined by the Company's internal reporting practices. In addition, gross sales

may not be realized in the form of cash receipts as promotional payments and allowances may be deducted from payments received from certain

customers. Mytesi gross sales are reduced by Medicare, ADAP 340B chargebacks, returns, and wholesale distribution fees based on historical

trends to determine net sales.

The Company defines non-GAAP EBITDA as net loss before interest expense

and other expense, depreciation of property and equipment, amortization of intangible assets, share-based compensation expense and provision

for or benefit from income taxes. The Company defines non-GAAP Recurring EBITDA as non-GAAP EBITDA adjusted for certain non-recurring

revenues and expenses. Company management believes that non-GAAP EBITDA and non-GAAP Recurring EBITDA are meaningful indicators of Jaguar's

performance and provide useful information to investors regarding the Company's results of operations and financial condition.

Participation Instructions for Webcast

When: Monday, May 17, 2021, at 8:30 AM Eastern

Participant Registration & Access Link: Click

Replay Instructions for Webcast

Dial-in (US Toll Free): 844-512-2921

Dial-in (International): 412-317-6671

Replay Pin Number: 5530970

Replay of the webcast on the investor relations

section of Jaguar's website (click here)

About Jaguar Health, Inc. and Napo Pharmaceuticals, Inc.

Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused

on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress,

specifically chronic, debilitating diarrhea. Our wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing

proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. Our Mytesi

(crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral

therapy and the only oral plant-based prescription medicine approved under FDA Botanical Guidance.

For more information about Jaguar, please visit https://jaguar.health.

For more information about Napo, visit www.napopharma.com.

Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic

relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi is not indicated for the treatment

of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi. If infectious etiologies are not considered,

there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical

studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis

(3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

See full Prescribing Information at Mytesi.com. Crofelemer,

the active ingredient in Mytesi, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton

lechleri tree in the Amazon rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree

of quality and ecological integrity.

Forward-Looking Statements

Certain statements in this press release constitute

"forward-looking statements." These include statements regarding the expectation that Jaguar will host an investor

webcast on May 17, 2021. In some cases, you can identify forward-looking statements by terms such as "may,"

"will," "should," "expect," "plan," "aim," "anticipate,"

"could," "intend," "target," "project," "contemplate,"

"believe," "estimate," "predict," "potential" or "continue" or the

negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar

has based these forward-looking statements largely on its current expectations and projections about future events. These

forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and

assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required

by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a

result of any new information, future events, changed circumstances or otherwise.

Source: Jaguar Health, Inc.